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results from the published literature, problems arise
where data are incomplete. Thus, more transparent re-
porting of study results are required to aid transferability.
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Coyle D, Lee KM
Clinical Epidemiology Unit, Loeb Health Research Institute, 
Ottawa Hospital, Ottawa, ON, Canada
OBJECTIVE: To address two specific issues relating to
the conduct of economic analysis based on decision ana-
lytic techniques: the impact on results of different sources
of both effectiveness and resource use data. METHODS:
Sensitivity analysis of erythropoietin use in orthopedic
surgery and alendronate in the treatment of osteoporosis.
Analysis focuses on the effect on the incremental cost-
effectiveness ratio of different sources of treatment effec-
tiveness and resource use. For effectiveness, analysis com-
pared results based on individual clinical trials and meta
analysis. Further analysis compared the results based on
resource use data from the clinical trials and data from
administrative data sets. RESULTS: Results varied greatly
between the different sources of effectiveness and re-
source use data. Based on outcomes from individual clin-
ical trials the cost per QALY gained from alendronate
varied from $27,000 to $104,500. The cost per QALY
gained from a meta analysis of all studies was $35,600.
The cost per life year gained of erythropoietin was more
than ten times greater using actual resource use data in
clinical practice in Ottawa than using trial based data.
CONCLUSIONS: Economic analysis conducted through
decision analytic techniques has been open to criticism
over the ease at which desired results can be obtained. By
adopting standards based on an evidence-based approach
to identifying parameters, such criticisms can be avoided.
Based on the results of this paper we recommend that
meta analysis is the preferred source of outcome data but
routine local data are the best source of resource use data.
PMT15
VALIDATION OF FRAMINGHAM REGRESSION 
EQUATIONS FOR LOCAL USE
Milne RJ1,2
1Health Outcomes Associates Ltd., Auckland, New Zealand; 
2University of Auckland, Auckland, New Zealand
Regression equations from the Framingham Heart Study
(FHS) are used in New Zealand to estimate individual
cardiovascular risk. However, these equations have not
been validated for use in the NZ population. OBJEC-
TIVES: To determine the applicability of FHS regression
equations to the Auckland population, to facilitate eco-
nomic modelling of the management of cardiovascular
risk. METHODS: Population risk profiles for Auckland
were used as inputs to recent FHS equations for CHD
events, stroke and myocardial infarction (MI). Annual
risk was calculated from 5-y risk using a Markov model.
The predictions were compared with 1998-92 MI and
stroke event rates obtained from the MONICA study in
Auckland, and with NZ CHD mortality rates. RE-
SULTS: FHS equations predict the risk of incident MI for
Auckland males age 40–64 within 20%, however they
over-estimate female MI risk by up to 2-fold. The FHS
predicts that CHD event risk stabilises over age 53 for fe-
males although NZ female CHD mortality rates (ICD9
410–414) increase exponentially up to age 80. A FHS
stroke equation fits males 60 years but overestimates
risk for younger men and underestimates stroke risk for
women age 40–74 by 33%. Age-specific relative risk for
females compared with males is consistent across Auck-
land CHD event and mortality data and also NZ CHD
mortality data. CONCLUSIONS: FHS equations with
Auckland risk profile inputs provide a reasonable esti-
mate of population MI risk for Auckland men but not for
women. MI risk for Auckland women can be estimated
from FHS risk for males multiplied by the relative risk
obtained from NZ CHD mortality data. Stroke risk pre-
dicted by the FHS is accurate for NZ men over 60 years
but systematically underestimates risk for NZ women.
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Commercial and private pilots require an annual risk of
an acute incapacitating cardiovascular (CVD) event
1% to maintain their medical certification. OBJEC-
TIVES: (1) to develop a precise, accurate method for esti-
mation of the risk of an acute, incapacitating cardiovas-
cular event, based on a clinical assessment plus blood
lipids, glucose determination and ECG; (2) to determine
the age at threshold for a range of risk profiles. METH-
ODS: Annual risk of CHD, MI and stroke were deter-
mined from recent Framingham regression equations val-
idated for New Zealand. The risk of an acute incapacitating
CHD event is bounded by MI risk and CHD risk. Age at
threshold was estimated from a weighted combination
of Framingham estimates, assuming that 20% of inci-
dent angina pectoris is incapacitating. RESULTS: A non-
diabetic, non-smoking male with age-specific average
Auckland population lipid profile and systolic blood
pressure will reach the 1% per annum threshold for an
incapacitating cardiovascular event at age 60. Males with
30% lower serum cholesterol and 20 points lower sys-
tolic blood pressure will reach the 1% threshold at age
69. Tobacco smoking reduces the age at threshold by 10
years and diabetes by 7 years for males and 12 years for
females. The age at threshold is 12 years higher for
women versus men with similar modifiable risk factors.
A male with several cardiovascular risk factors could
